Design, synthesis and evaluation of a series of non-steroidal anti-inflammatory drug conjugates as novel neuroinflammatory inhibitors

International Immunopharmacology

Volumn 25, Issue 2, 2015, Pages 528-537

  Xu, Zhixiang ^a   Wu, Jing ^a   Zheng, Jiyue ^a   Ma, Haikuo ^a   Zhang, Hongjian ^a   Zhen, Xuechu ^a   Zheng, Long Tai ^a   Zhang, Xiaohu ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Drug conjugates; Microglia activation; Neurodegenerative diseases; Neuroinflammation; Neuroprotection

Indexed keywords

CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; NEUROINFLAMMATORY INHIBITOR; NEUROPROTECTIVE AGENT; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN-6, MOUSE; NITRITE; NOS2 PROTEIN, MOUSE; PROSTAGLANDIN E2; PTGS2 PROTEIN, MOUSE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVATION; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANIMAL; CELL LINE; COCULTURE; DRUG EFFECTS; GENETICS; METABOLISM; NERVE CELL; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYCLOOXYGENASE 2; DINOPROSTONE; DRUG DESIGN; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MICE; MICROGLIA; NEURONS; NEUROPROTECTIVE AGENTS; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924757482     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2015.02.033     Document Type: Article

References (57)

1. M.L. Block, L. Zecca, and J.S. Hong Microglia-mediated neurotoxicity: uncovering the molecular mechanisms Nat Rev Neurosci 8 2007 57 69
2. A. Klegeris, E.G. McGeer, and P.L. McGeer Therapeutic approaches to inflammation in neurodegenerative disease Curr Opin Neurol 20 2007 351 357
3. G.W. Kreutzberg Microglia: a sensor for pathological events in the CNS Trends Neurosci 19 1996 312 318
4. B. Liu, and J.S. Hong Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention J Pharmacol Exp Ther 304 2003 1 7
5. P.G. Conaghan A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity Rheumatol Int 32 2012 1491 1502
6. J.R. Vane Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Nat New Biol 231 1971 232 235
7. L. Minghetti Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases J Neuropathol Exp Neurol 63 2004 901 910
8. M.A. Ajmone-Cat, A. Bernardo, A. Greco, and L. Minghetti Non-steroidal anti-inflammatory drugs and brain inflammation: effects on microglial functions Pharmaceuticals 3 2010 1949 1965
9. J.M. Parepally, H. Mandula, and Q.R. Smith Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, flurbiprofen, and indomethacin Pharm Res 23 2006 873 881
10. J.E. Keeble, and P.K. Moore Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs Br J Pharmacol 137 2002 295 310
11. B. Everts, P. Wahrborg, and T. Hedner COX-2-Specific inhibitors - the emergence of a new class of analgesic and anti-inflammatory drugs Clin Rheumatol 19 2000 331 343
12. J.L. Wallace Hydrogen sulfide-releasing anti-inflammatory drugs Trends Pharmacol Sci 28 2007 501 505
13. L. Li, G. Rossoni, A. Sparatore, L.C. Lee, P. Del Soldato, and P.K. Moore Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative Free Radic Biol Med 42 2007 706 719
14. C. Szabo Hydrogen sulphide and its therapeutic potential Nat Rev Drug Discov 6 2007 917 935
15. G. Caliendo, G. Cirino, V. Santagada, and J.L. Wallace Synthesis and biological effects of hydrogen sulfide (H2S): development of H2S-releasing drugs as pharmaceuticals J Med Chem 53 2010 6275 6286
16. L. Li, M. Bhatia, and P.K. Moore Hydrogen sulphide - a novel mediator of inflammation? Curr Opin Pharmacol 6 2006 125 129
17. M. Lee, A. Sparatore, P. Del Soldato, E. McGeer, and P.L. McGeer Hydrogen sulfide-releasing NSAIDs attenuate neuroinflammation induced by microglial and astrocytic activation Glia 58 2010 103 113
18. M. Besouw, R. Masereeuw, L. van den Heuvel, and E. Levtchenko Cysteamine: an old drug with new potential Drug Discov Today 18 2013 785 792
19. T. Fujisawa, B. Rubin, A. Suzuki, P.S. Patel, W.A. Gahl, and B.H. Joshi Cysteamine suppresses invasion, metastasis and prolongs survival by inhibiting matrix metalloproteinases in a mouse model of human pancreatic cancer PLoS One 7 2012 e34437
20. J.K. Andersen Oxidative stress in neurodegeneration: cause or consequence? Nat Med 10 Suppl. 2004 S18 S25
21. E. Gaggelli, H. Kozlowski, D. Valensin, and G. Valensin Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis) Chem Rev 106 2006 1995 2044
22. P.M. Doraiswamy, and A.E. Finefrock Metals in our minds: therapeutic implications for neurodegenerative disorders Lancet Neurol 3 2004 431 434
23. S.A. Hitchcock, and L.D. Pennington Structure-brain exposure relationships J Med Chem 49 2006 7559 7583
24. A. Kourounakis, K. Tsiakitzis, D. Paramithiotis, K. Kotzampassi, and P. Kourounakis Effect of a novel NSAID derivative with antioxidant moiety on oxidative damage caused by liver and cerebral ischaemia reperfusion in rats J Pharm Pharmacol 54 2002 1091 1096
25. J.A. Baur, and D.A. Sinclair Therapeutic potential of resveratrol: the in vivo evidence Nat Rev Drug Discov 5 2006 493 506
26. N. Singh, M. Agrawal, and S. Dore Neuroprotective properties and mechanisms of resveratrol in in vitro and in vivo experimental cerebral stroke models ACS Chem Neurosci 4 2013 1151 1162
27. L. Buryanovskyy, Y. Fu, M. Boyd, Y. Ma, T.C. Hsieh, and J.M. Wu Crystal structure of quinone reductase 2 in complex with resveratrol Biochemistry 43 2004 11417 11426
28. K.L. Khanduja, A. Bhardwaj, and G. Kaushik Resveratrol inhibits N-nitrosodiethylamine-induced ornithine decarboxylase and cyclooxygenase in mice J Nutr Sci Vitaminol (Tokyo) 50 2004 61 65
29. K.T. Howitz, K.J. Bitterman, H.Y. Cohen, D.W. Lamming, S. Lavu, and J.G. Wood Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan Nature 425 2003 191 196
30. M. Kaeberlein, T. McDonagh, B. Heltweg, J. Hixon, E.A. Westman, and S.D. Caldwell Substrate-specific activation of sirtuins by resveratrol J Biol Chem 280 2005 17038 17045
31. M.T. Borra, B.C. Smith, and J.M. Denu Mechanism of human SIRT1 activation by resveratrol J Biol Chem 280 2005 17187 17195
32. T. Walle, F. Hsieh, M.H. DeLegge, J.E. Oatis Jr., and U.K. Walle High absorption but very low bioavailability of oral resveratrol in humans Drug Metab Dispos 32 2004 1377 1382
33. L.T. Zheng, J. Hwang, J. Ock, M.G. Lee, W.H. Lee, and K. Suk The antipsychotic spiperone attenuates inflammatory response in cultured microglia via the reduction of proinflammatory cytokine expression and nitric oxide production J Neurochem 107 2008 1225 1235
34. L. Tao, F. Zhang, L. Hao, J. Wu, J. Jia, and J.Y. Liu 1-O-Tigloyl-1-O-deacetyl-nimbolinin B inhibits LPS-stimulated inflammatory responses by suppressing NF-kappaB and JNK activation in microglia cells J Pharmacol Sci 125 2014 364 374
35. Y.X. Yang, L.T. Zheng, J.J. Shi, B. Gao, Y.K. Chen, and H.C. Yang Synthesis of 5alpha-cholestan-6-one derivatives and their inhibitory activities of NO production in activated microglia: discovery of a novel neuroinflammation inhibitor Bioorg Med Chem Lett 24 2014 1222 1227
36. L.T. Zheng, J. Ock, B.M. Kwon, and K. Suk Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity Int Immunopharmacol 8 2008 484 494
37. X. Zhou, P. Gan, L. Hao, L. Tao, J. Jia, and B. Gao Antiinflammatory effects of orientin-2″-o-galactopyranoside on lipopolysaccharide-stimulated microglia Biol Pharm Bull 37 2014 1282 1294
38. K. Saijo, and C.K. Glass Microglial cell origin and phenotypes in health and disease Nat Rev Immunol 11 2011 775 787
39. L.M. Zhong, Y. Zong, L. Sun, J.Z. Guo, W. Zhang, and Y. He Resveratrol inhibits inflammatory responses via the mammalian target of rapamycin signaling pathway in cultured LPS-stimulated microglial cells PLoS One 7 2012 e32195
40. G. Stoll, and S. Jander The role of microglia and macrophages in the pathophysiology of the CNS Prog Neurobiol 58 1999 233 247
41. C.V. Jongeneel Transcriptional regulation of the tumor necrosis factor alpha gene Immunobiology 193 1995 210 216
42. P.A. Baeuerle, and T. Henkel Function and activation of NF-kappa B in the immune system Annu Rev Immunol 12 1994 141 179
43. M.P. Mattson, and S. Camandola NF-kappaB in neuronal plasticity and neurodegenerative disorders J Clin Invest 107 2001 247 254
44. A. Lleo, E. Galea, and M. Sastre Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases Cell Mol Life Sci 64 2007 1403 1418
45. J. Frantzias, J.G. Logan, P. Mollat, A. Sparatore, P. Del Soldato, and S.H. Ralston Hydrogen sulphide-releasing diclofenac derivatives inhibit breast cancer-induced osteoclastogenesis in vitro and prevent osteolysis ex vivo Br J Pharmacol 165 2012 1914 1925
46. V. Waetzig, K. Czeloth, U. Hidding, K. Mielke, M. Kanzow, and S. Brecht c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia Glia 50 2005 235 246
47. M. Karin The regulation of AP-1 activity by mitogen-activated protein kinases J Biol Chem 270 1995 16483 16486
48. M. Guha, and N. Mackman LPS induction of gene expression in human monocytes Cell Signal 13 2001 85 94
49. R. Singh, R.P. Cadeddu, J. Frobel, C.M. Wilk, I. Bruns, and L.F. Zerbini The non-steroidal anti-inflammatory drugs Sulindac sulfide and Diclofenac induce apoptosis and differentiation in human acute myeloid leukemia cells through an AP-1 dependent pathway Apoptosis 16 2011 889 901
50. D. Galanakis, A.P. Kourounakis, K.C. Tsiakitzis, C. Doulgkeris, E.A. Rekka, and A. Gavalas Synthesis and pharmacological evaluation of amide conjugates of NSAIDs with l-cysteine ethyl ester, combining potent antiinflammatory and antioxidant properties with significantly reduced gastrointestinal toxicity Bioorg Med Chem Lett 14 2004 3639 3643
51. V.R. Shanbhag, A.M. Crider, R. Gokhale, A. Harpalani, and R.M. Dick Ester and amide prodrugs of ibuprofen and naproxen: synthesis, anti-inflammatory activity, and gastrointestinal toxicity J Pharm Sci 81 1992 149 154
52. S. Ghosh, M.J. May, and E.B. Kopp NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses Annu Rev Immunol 16 1998 225 260
53. H. Kan, Z. Xie, and M.S. Finkel TNF-alpha enhances cardiac myocyte NO production through MAP kinase-mediated NF-kappaB activation Am J Physiol 277 1999 H1641 H1646
54. M. Doi, M. Shichiri, K. Katsuyama, F. Marumo, and Y. Hirata Cytokine-activated p42/p44 MAP kinase is involved in inducible nitric oxide synthase gene expression independent from NF-kappaB activation in vascular smooth muscle cells Hypertens Res 23 2000 659 667
55. H.Y. Park, M.H. Han, C. Park, C.Y. Jin, G.Y. Kim, and I.W. Choi Anti-inflammatory effects of fucoidan through inhibition of NF-kappaB, MAPK and Akt activation in lipopolysaccharide-induced BV2 microglia cells Food Chem Toxicol 49 2011 1745 1752
56. A. Kessler, M. Biasibetti, D.A. da Silva Melo, M. Wajner, C.S. Dutra-Filho, and Â.T. de Souza Wyse Antioxidant effect of cysteamine in brain cortex of young rats Neurochem Res 33 2008 737 744
57. C. Gibrat, and F. Cicchetti Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases Prog Neuropsychopharmacol Biol Psychiatry 35 2011 380 389